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Abstract
Background: The aim of this study was to develop a scoring system for prediction of survival prognosis after
surgery in patients with symptomatic metastatic spinal cord compression (MSCC) from non-small cell lung
cancer (NSCLC).
Methods: We retrospectively analyzed nine preoperative characteristics for survival in a series of 64 patients with
NSCLC who were operated with posterior decompression and spine stabilization for MSCC. Characteristics significantly
associated with survival on multivariate analysis were included in the scoring system. The scoring point for each
significant characteristic was derived from the hazard ratios on Cox proportional hazards model. The total score for
each patient was obtained by adding the scoring points of all significant characteristics.
Results: Eastern Cooperative Oncology Group (ECOG) performance status, number of involved vertebrae, visceral
metastases, and time developing motor deficits had significant impact on survival on multivariate analysis and were
included in the scoring system. According to the prognostic scores, which ranged from 4 to 10 points, three
prognostic groups were designed: 4–5 points (n = 22), 6–7 points (n = 23), and 8–10 points (n = 19). The corresponding
6-month survival rates were 95, 47 and 11 %, respectively (P < 0.0001). In addition, the functional outcome was worse
in the group of patients with 8–10 points compared with other two prognostic groups.
Conclusions: The new scoring system will enable physicians to identify patient with MSCC from NSCLC who may
be a candidate for decompression and spine stabilization, more radical surgery, or supportive care alone. Patients
with scores of 4–5, who have the most favorable survival prognosis and functional outcome, can be treated with
more radical surgery in order to realize better local control of disease and prevent the occurrence of local
disease. Patients with scores of 6–7 points should be surgical candidates, because survival prognosis and
functional outcome are acceptable after surgery, while patients with scores of 8–10 points, who have the shortest
survival time and poorest functional outcome after surgery, appear to be best treated with radiotherapy or best
supportive care.
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Background
Metastatic spinal cord compression (MSCC) is a severe
complication of cancer that occurs in 28 % of patients
with lung cancer and can become symptomatic, which in-
volves intractable pain, disability, and incontinence [1–3],
negatively impacting the patient's quality of remaining life.
The optimal treatments for patients with MSCC are anal-
gesics, corticosteroids, chemotherapy, radiotherapy and
surgery, and most often these treatments are combined to
give the maximum palliative effect with a minimum of
operative morbidity and mortality [1, 4, 5], positively
improving the patient's quality of remaining life. Recently,
an increasing number of studies supported the use of
decompressive surgery as an effective treatment for
MSCC due to the evolvement of surgical techniques [1,
2, 6], while only a few studies specifically addressed sur-
gical treatment of MSCC in lung cancer [7, 8], which
was often associated with high morbidity and mortality
[8]. A major problem in selection patients for surgery is
to avoid operating on those who are likely to die very
soon after surgery, so life expectancy is the most im-
portant selection criteria for surgery. While for patients
with very short survival time radiotherapy or best sup-
portive care alone are recommended, for patients with
more favorable prognosis can be treated with decom-
pressive surgery, or even more radical surgery such as
excisional procedures [4, 9, 10].
Some scoring systems were designed to estimate the sur-
vival time of each patient and select the optimal treatment
strategy among supportive care, palliative radiotherapy,
palliative surgery, and excisional surgery [9–15]. However,
some old and commonly-used scoring systems have
underestimated the life expectancy of lung cancer patients
with spinal metastases because of the increased survival
time for this patient group in recent years [16–19].
Notably, it is critical to regard patients with MSCC
from a particular primary tumor type as a separate
group of patients for individual treatment, because pri-
mary tumors vary with respect to their biological be-
havior. Therefore, our present study is designed to
develop a new survival score particularly for patients




Sixty-four patients with NSCLC operated with decom-
pression and spine stabilization for MSCC were retro-
spectively analyzed in the study at the Affiliated
Hospital of Academy of Military Medical Sciences,
Beijing, between May 2005 and May 2015. The diag-
nosis of bone metastasis in NSCLC patients was con-
firmed histologically, adequate diagnostic imaging
including spinal CT or MRI, as well as bone scan.
Patients with an estimated survival less than 3 months
or health too poor to undergo surgery were excluded.
Of the total series of 64 patients, six patients were
treated with radical resection of primary lung cancer,
while others weren’t. The data were collected from
patients, their family members, treating surgeons, and
patients’ files. The Medical Research Ethics Board of
the Affiliated Hospital of Academy of Military Med-
ical Sciences approved this retrospective study and re-
quired neither patient approval nor informed consent
for review of patients’ images and medical records.
The data were retrospective in nature and anon-
ymized by the Medical Research Ethics Board.
Table 1 Univariate analysis of preoperative factors for
postoperative survival in patients with MSCC from NSCLC
Factors Patients (n) Survival MOS
(mo)
P
6 mo (%) 12 mo (%)
Age
≤ 57 years 34 61 27 7.1 0.16
≥ 58 years 30 42 18 4.8
Gender
Female 22 55 23 6.3 0.90
Male 42 52 24 6.2
Preoperative ambulatory status
Ambulatory 33 64 32 8.8 0.003
Nonambulatory 31 41 14 4.8
Other bone metastases
No 16 69 21 7.9 0.58
Yes 48 47 23 4.9
ECOG performance status
1–2 43 66 29 8.8 <0.001
3–4 21 26 5 4.5
Number of involved vertebrae
1–2 36 67 35 7.9 0.001
≥ 3 28 36 9 4.4
Visceral metastases
No 33 78 36 10.8 0.002
Yes 31 27 10 4.3
Interval from cancer diagnosis to surgery
≤ 80 days 32 59 24 7.1 0.73
> 80 days 32 47 22 5.5
Time developing motor deficits
≤ 14 days 30 30 7 3.9 <0.001
> 14 days 34 72 37 10.8
MSCC indicates metastatic spinal cord compression; NSCLC, non-small cell lung
cancer; MOS, median overall survival; MO, months; ECOG, Eastern Cooperative
Oncology Group
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Survival analysis
We retrospectively analyzed nine preoperative characteris-
tics for survival, including age (≤57 years vs. ≥58 years;
median age: 57 years), gender (female vs. male), preopera-
tive ambulatory status (ambulatory vs. nonambulatory),
other bone metastases (no vs. yes), Eastern Cooperative
Oncology Group (ECOG) performance status (1–2 vs. 3–
4), number of involved vertebrae (1–2 vs. ≥3, conformed
to previous studies), visceral metastases (no vs. yes), inter-
val from cancer diagnosis to surgery (≤80 days vs. >80 days;
median time: 80 days), and the time developing motor
deficits before surgery (≤14 days vs. >14 days, conformed
to previous studies).
The postoperative survival was defined as the time be-
tween the date of surgery and death or the latest follow-
up. For the present study, we included all 64 patients
with NSCLC who had decompressive surgery and spine
stabilization due to spinal cord compression. None of
the patients were excluded for any reason. 5 patients
were still alive by the end of the study period, with a
mean follow-up of 9.7 months in those patients. In pa-
tients who had surgery for more than one metastasis, all
Fig. 1 Kaplan-Meier survival curves for preoperative factors: (a) Preoperative ambulatory status, (b) ECOG performance status, (c) Number of
involved vertebrae, (d) Visceral metastases, and (e) Time developing motor deficits
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sites were included in the analysis. However, only the
first surgical procedure was accounted for in the survival
analysis.
Surgery and functional evaluation
The indication for surgery was neurological deficit due
to spinal cord compression. All patients were operated
with posterior decompression and stabilization in our
department. Local radiotherapy, systemic chemother-
apy, and targeted therapy with gefitinib were performed
after the wound healed, about 3–4 weeks after the
surgery. Postoperative functional outcome was analyzed
according to the scoring system. Neurological function
was graded based on Frankel et al. [20] preoperatively
and 4 weeks postoperatively (Patients with Frankel D
and E have the ability to walk). Time developing motor
deficits was defined as the time between deterioration
of motor function to disability or surgery. Deterioration
of motor function was defined as a change of at least
one Frankel grade.
Statistical analysis
The univariate analysis of survival was performed using
the Kaplan-Meier method and the log-rank test. The
significant prognostic factors (P < 0.05) were additionally
evaluated in a multivariate analysis performed with the
Cox proportion hazards model (multiple Cox regression,
selection = stepwise). The prognostic factors that were
significant in the multivariate analysis were included in
the scoring system. The prognostic factors that were
excluded by Cox proportion hazards model (multiple
Cox regression, selection = stepwise) were not included
in the scoring system. The scoring point for each signifi-
cant factors was derived from the hazard ratios on Cox
proportional hazards model (simple Cox regression).
The total prognostic score for each patient was deter-
mined by adding the scoring points of every signifi-
cant factor. Neurological outcome in risk groups was
compared with Chi-square test and Fisher exact test.
A P value of 0.05 or less was considered statistically
significant. Statistical analysis was performed using
SAS 9.2 software.
Results
Patient characteristics and survival
A total of 64 patients were included in the study, 34 % (22/
64) of patients were female, and 66 % (42/64) were male.
The overall median age was 57 years old. The median time
interval from diagnosis to surgery was 80 days, and the
median time developing motor deficits was 14 days.
For all patients, the overall median survival time was
6.3 months (95 % confidence interval, 4.5–7.4 months),
6-month and 12-month survival rates were 52.6 and
23 %, respectively. At the latest follow-up, 5 patients
were still alive, with a mean follow-up of 9.7 months.
Scoring system
On the univariate analysis, survival was significantly as-
sociated with preoperative ambulatory status (P = 0.003),
ECOG performance status (P < 0.001), number of in-
volved vertebrae (P = 0.001), visceral metastases (P =
0.002), and time developing motor deficits (P < 0.001,
Table 2 The Cox proportional hazards model analysis of preoperative factors for postoperative survival in patients with MSCC from
NSCLC
Factors Simple cox regression Multiple cox regression
HR (95 % CI) P HR (95 % CI) P
Preoperative ambulatory status 2.24 (1.30–3.86) 0.004 Excludeda
ECOG performance status 2.78 (1.54–5.02) <0.001 2.18 (1.15–4.16) 0.017
Number of involved vertebrae 2.46 (1.39–4.35) 0.002 2.05 (1.11–3.76) 0.021
Visceral metastases 2.29 (1.33–3.94) 0.003 2.00 (1.10–3.62) 0.022
Time developing motor deficits 3.44 (1.90–6.22) <0.001 2.70 (1.45–5.03) 0.002
MSCC indicates metastatic spinal cord compression; NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; CI, confidence interval
aSelection = stepwise, preoperative ambulatory status was excluded in the model
Table 3 Hazard ratio and corresponding scores of each significant
factors in the scoring system
Factors Patients (n) HR Scoring points
ECOG performance status
1–2 43 1 1
2–4 21 2.78 3
Number of involved vertebrae
1–2 36 1 1
≥ 3 28 2.46 2
Visceral metastases
No 33 1 1
Yes 31 2.29 2
Time developing motor deficits
< 14 days 30 3.44 3
≥ 14 days 34 1 1
HR indicates hazard ratio, ECOG Eastern Cooperative Oncology Group
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Fig. 1, Table 1). On Cox proportional hazards model (mul-
tiple Cox regression, selection = stepwise), four of above
five factors, ECOG performance status (P = 0.017), num-
ber of involved vertebrae (P = 0.021), visceral metastases
(P = 0.022), and time developing motor deficits (P =
0.002), maintained significant impact on survival and were
included in the scoring system (Table 2). The scoring
points for each of the four significant factors obtained
from the hazard ratios on Cox proportional hazards
model (simple Cox regression) were seen in Table 3. The
prognostic score for each patient was calculated by adding
the scoring points of the four significant characteristics.
The addition resulted in prognostic scores of 4, 5, 6, 7, 8,
9, 10 points. The 6-month survival rates of the prognostic
scores were shown in Fig. 2. Taking into account the 6-
month survival rates of the prognostic scores, the
following three survival groups were formed: 4–5 points
(group A, n = 22), 6–7 points (group B, n = 23), and 8–10
Fig. 2 The total scores and corresponding 6-month survival rates (%)
Fig. 3 Kaplan-Meier survival curves for three prognostic groups based on the new scoring system (P < 0.001, log-rank test)
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points (group C, n = 19). The corresponding median sur-
vival times were 12.8 months (95 % confidence interval,
8.8–18.7 months), 6.4 months (95 % confidence interval,
3.8–7.4 months) and 2.7 months (95 % confidence interval,
1.5–4.5 months), respectively, and 6-month survival rates
were 95, 47 and 11 %, respectively (P < 0.001, Fig. 3).
Functional outcome
The functional outcome was worse in the group of
patient with 8–10 points (group C) compared with the
other two prognostic groups (Table 4). In detail, 86 %
(19/22) patients were ambulatory 4 weeks after surgery
in group A, 74 % (17/23) patients in group B, and only
42 % (8/19) patients in group C.
In the entire cohort of 64 patients, 68.8 % (44 of 64) of
the patients were able to walk 4 weeks after decompres-
sion, 51.6 % (16/31) of nonambulatory patients before op-
eration regained the ability to walk, and 84.8 % (28/33) of
ambulatory patients maintained their neurological status,
whereas 15.2 % (5/33) of ambulatory patients before sur-
gery lost their ability to walk for disease progression. Six
patients died within 4 weeks after surgery and none of
them achieved ambulation.
Discussion
Individually treatment needs to be planned for each pa-
tient with MSCC to give the maximum palliative effect:
reduction in pain, recovery of function, and improve-
ment in the patient’s quality of remaining life. Selection
of the optimal treatment for the individual patient with
MSCC should take into account patient’s estimated sur-
vival time, as well as functional outcome after therapies.
Only those who survive long enough, more than
3 months, can benefit from surgery [21, 22]. In contrast,
patients with very short survival time and poor func-
tional outcome appear to be best treated with radiother-
apy or even best supportive care alone, which means less
discomfort for these debilitated and enervated patient [4,
10]. Remarkably, it is also critical to regard patients with
MSCC from a particular primary tumor type as a separ-
ate group of patients for optimal treatment, because pri-
mary tumors vary with respect to their biological
behavior. Crnalic et al. [23] presented a score specifically
for predicting survival of patients with prostate cancer
after surgery for MSCC. However, who may benefit from
surgery, and what kind of patients are appropriate for
supportive care, remains nuclear in NSCLC patients
with MSCC.
Several scoring systems have been proposed for predict-
ing survival in patient with spinal metastasis on the basis
of retrospective data from various primary tumors treated
with surgery or radiotherapy alone. However, these scores
comprised relatively small number of patient with lung
cancer (Tokuhashi 6 [9], revised Tokuhashi 26 [10],
Tomita 10 [11], Van der Linden 68 [12], Sioutos 45 [13],
Bauer 6 [14], Bartels 28 [15], more details were seen in
Table 5), making it difficult to draw conclusions on this
specific tumor type.
Although the revised Tokuhashi was found to be use-
ful to predict survival for patients with spinal metasta-
ses from breast cancer alone [4] or solid cancers [24,
25], which seems to be a suboptimal tool for the predic-
tion of an individual prognosis in the group of patients
with lung cancer (Hessler et al. [16]). In their study, 67
patients with spinal metastasis from lung cancer, all of
them underwent surgical treatment. Hessler et al. [16]
concluded that the Tokuhashi scoring system underes-
timated the life expectancy of lung cancer patients due
to the increased survival time for this patient group. In
2013, Morgen et al. [17] also found a statistically sig-
nificant increase in survival over the years for lung can-
cer patients with MSCC (n = 2321, 499 patients with
lung cancer, 103 lung cancer patients received surgical
treatment). For patients with lung cancer who under-
went surgery for MSCC, survival increased from 9 % in
year 2005 up to 30 % in year 2010 (P = 0.047). More re-
cent studies have reported improvements among patients
with advanced lung cancer because of the new treatment
options [18, 19]. Therefore, with the increasing survival
time of patients with lung cancer during recent years, the
Tokuhashi scoring system and other scores may no longer
be suitable for patients with lung cancer.
Furthermore, these scores were designed for patients
with spinal metastasis in general, not particularly for pa-
tients with motor impairment due to MSCC. Rades et al.
[26] developed and validated a scoring system for survival
Table 4 Neurological recovery of the patients in 3 prognostic groups 4 weeks after surgery
Groups Scores Patients(n) Neurological status weeks postoperation P values
Ambulatory Nonambulatory
A 4–5 22 19 3 P1 = 0.502
B 6–7 23 17 6 P2 = 0.037
C 8–10 19 8 11a P3 = 0.003
P1 Group A compared with group B, Continuity Adjusted Chi-square test;
P2 Group B compared with group C, Chi-square test;
P3 Group C compared with group A, Chi-square test
a2 patients died within 4 weeks, none of both realized ambulatory status
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of patients (n = 356, all patients with lung cancer) with
MSCC from NSCLC who had been treated with radiother-
apy alone. Aside from the Rades score, the above men-
tioned scoring systems included relatively small number
of patients with spinal metastasis from various primary
tumors. In fact, participants in Rades score received radio-
therapy alone, and the functional outcome was not con-
sidered either. Moreover, patients who had prior surgery
to the involved parts of the spinal cord were excluded in
their study.
Table 5 Commonly-used and our scoring systems for patient with spinal metastasesa
Scoring systems MOS (m) Suggestions No. of LC (Total) Spinal metastasis Treatments Parameters
Tokuhashi [9]
Group A 3 Palliative surgery 6 (64) In general All surgeryc PS; Extraspinal bone metastases;
Metastases in the vertebral body;
Metastases to major organs;
primary tumor site; Spinal
cord palsy
Group B 6 -
Group C 22 Excisional surgery
Revised Tokuhashi [10]
Group A 4.9 Conservation therapy 26 (246) In general 164 patients was
treated with surgery
PS; Extraspinal bone metastases;
Metastases in the vertebral body;
Metastases to major organs;
Primary tumor site; Spinal
cord palsy
Group B 9.5 Palliative surgery
Group C 19 Excisional surgery
Tomita [11]
Group A 6 Supportive care 10 (67) In general 58 patients was
treated with surgery
No. of extraspinal bone metastases;
Metastases to major internal organs;
Primary tumor site; Spinal cord palsyGroup B 15 Palliative surgery
Group C 24 Intralesional/marginal
Group D 50 Excisional surgery
Van der Linden [12]
Group A 4.8 Radiotherapy 68 (324) No MSCC Radiotherapy alone KPS; Primary tumor;
Visceral metastases
Group B 13.1 Radiotherapy
Group C 18.3 Surgery
Sioutos [13]
3b 1.5 No surgery 45 (109) MSCC All surgeryd Preoperative neurological status;
Anatomic site of primary
carcinoma; No. of vertebral
bodies involved
2b 6.0 No surgery
1b 11.2 Radical surgery
0b 18.0 Radical surgery
Bauer [14]
Group A - No surgery 6 (88) In general All surgerye Visceral metastases; No. of skeletal
metastases; Primary cancer type.
Group B - Dorsal surgery
Group C - Ventral-dorsal surgery
Bartels [15]
Not reported 28 (219) In general Radiotherapy alone Sex; Location of the primary lesion;
Curative treatment of the primary
tumor; Location of the spinal
metastasis; KPS
Ours
Group A 12.8 More radical surgery 64 (64) MSCC All surgerye ECOG performance status; No.
of involved vertebrae; Visceral
metastases; Time developing
motor deficits.
Group B 6.4 Depressive surgery
Group C 2.7 Supportive care
MOS indicates mean overall survival; LC, lung cancer; PS, performance status; KPS, karnofsky performance status; MSCC, metastatic spinal cord compression,
ECOG, Eastern Cooperative Oncology Group
aFunctional outcome are not considered in all of their original studies
bNo. of negative prognostic factors
cExcisional or palliative procedure
dAnterior or posterior approach
ePosterior approach
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In our study, a score was developed based on the data
derived from 64 patients with NSCLC who underwent
decompressive surgery and spine stabilization for MSCC.
The indication for surgery was neurological deficits.
Functional outcome was also considered according to
the scoring system. The patient’s individual situation,
therefore, is taken more into account in the present
scoring system. Patients with scores of 4–5 survived
more than 1 year in median time, and 86 % patients
were ambulatory 4 weeks after surgery. More radical
surgery, such as widely excision of vertebra metastasis,
can be considered in order to realize better local control
of disease and prevent the occurrence of local disease in
those patients. Patients with scores of 6–7 points should
be surgical candidates, because survival prognosis and
functional outcome were favorable after surgery. Patients
with scores of 8–10 points, who survived 2.7 months in
median time and had the worst functional outcome after
surgery compared with other two prognostic groups, ap-
peared to be best treated with radiotherapy or best support-
ive care alone. Functional outcome was acceptable in the
entire cohort of 64 patients, 68.8 % (44 of 64) patients were
able to walk 4 weeks after decompression; 51.6 % (16/31) of
nonambulatory patients before operation regained the abil-
ity to walk. 74–84 % patients were able to walk after surgery
[6, 7, 27] and 22–68 % of nonambulatory patients became
ambulatory again in other studies [7 28].
However, patients with asymptomatic MSCC were not
included in our study, so this scoring system doesn’t
pertain to those patients. Besides, our score was based
on retrospective data, and the statistical analysis didn’t
include a relatively larger number of patients, and data
on systemic treatment following treatment was not avail-
able in most patients. Despite good predictive value in
our scoring system, the score still warrants a prospective
study to be confirmed.
Conclusion
We present a new score for predicting survival of patients
with NSCLC operated with posterior decompression
and spine stabilization for MSCC. Functional outcome
after surgery was also considered in our study. The scor-
ing system can help select the individual treatment for pa-
tients with MSCC from NSCLC. Patients with scores of
4–5, who have the most favorable survival prognosis and
functional outcome, can be treated with more radical
surgery in order to realize better local control of dis-
ease and prevent the occurrence of local disease. Pa-
tients with scores of 6–7 points should be surgical
candidates, because survival prognosis and functional
outcome are acceptable after surgery, while patients
with scores of 8–10 points, who have the shortest
survival time and poorest functional outcome after
surgery, appear to be best treated with radiotherapy
or best supportive care. Still, a prospective study is
needed.
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